Search Results

Your search for Daniel Morgensztern, MD, and Roy S. Herbst, MD, PhD,Daniel Morgensztern, MD, and Roy S. Herbst, MD, PhD matches 2 pages

Showing 1 - 2

By Matthew Stenger / August 15 2012

No Improvement in Overall Survival, Worse Toxicity with Motesanib Added to Chemotherapy in Non–Small Cell Lung Cancer

Two trials (E4599 and AVAiL) have suggested a benefit to adding the anti–vascular endothelial growth factor (VEGF) monoclonal antibody bevacizumab (Avastin) to chemotherapy in patients with advanced nonsquamous non–small cell lung cancer (NSCLC). Bevacizumab acts by binding directly to circulating...

lung cancer

By Daniel Morgensztern, MD, and Roy S. Herbst, MD, PhD / January 15, 2014

Adjuvant Gefitinib in Patients With NSCLC: Bad Idea or Wrong Patient Selection?

Despite optimal surgical resection and adjuvant chemotherapy with cisplatin-based doublets, the 5-year overall survival for patients with early-stage non–small cell lung cancer (NSCLC) remains suboptimal. In the International Association for the Study of Lung Cancer (IASLC) staging project, the...

Nov

Today In Oncology

Search Results

Your search for Daniel Morgensztern, MD, and Roy S. Herbst, MD, PhD,Daniel Morgensztern, MD, and Roy S. Herbst, MD, PhD matches 2 pages

No Improvement in Overall Survival, Worse Toxicity with Motesanib Added to Chemotherapy in Non–Small Cell Lung Cancer

Adjuvant Gefitinib in Patients With NSCLC: Bad Idea or Wrong Patient Selection?

What Is the Impact of a Colon or Colorectal Cancer Diagnosis on Younger Adults?

International Cancer Organizations Present Collaborative Work During Oncology Event in China

Is There a Role for Neoadjuvant Chemotherapy in HR-Positive, HER2-Negative Early Breast Cancer?

Suicide-Related Mortality in Male AYA Cancer Survivors

Four-Year Asian Subpopulation Data From the CheckMate 816 Trial of Neoadjuvant Nivolumab Plus Chemotherapy in Resectable NSCLC